Information  X 
Enter a valid email address

Diurnal Group PLC (DNL)

  Print      Mail a friend

Wednesday 15 July, 2020

Diurnal Group PLC

Director Dealings

RNS Number : 1096T
Diurnal Group PLC
15 July 2020
 

15 July 2020

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following Director's dealing:

 

Richard Bungay, Chief Financial Officer, sold 41,873 Ordinary Shares at a price of 30.25 pence per Ordinary Share in order to fund his personal tax liability arising from the vesting of his deferred bonus award of 86,066 Ordinary Shares, as detailed in the RNS announcement dated 13 July 2020. Following the sale of shares the total beneficial interest of Richard Bungay is 107,109 Ordinary Shares, representing 0.09% of the total voting rights.

 

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Richard Bungay

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Sale of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




0.3025

41,873

 

 






d)

 

Aggregated information




- Aggregated volume

As above



- Price




e)

 

Date of the transaction

 

15 July 2020

f)

 

Place of the transaction

 

XLON

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Sole Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: James Stearns




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


 

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK headquartered, European-based specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFLFELDAIELII

a d v e r t i s e m e n t